Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

Faced with huge debt, the impending expiry of a crucial patent, and ongoing litigation over a horror acquisition, Bayer CEO Bill Anderson made a bold move a year ago to get his damaged company ...

As we usher in 2025, it’s the perfect time to prioritize health and wellness. Recently, Registered Dietitian & Nutritionist Kelly Bristow from Bayer, one of the country's largest life-sciences ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

Bayer cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads ...

Leadership Strategist Dan Pontefract covers leadership and culture. Heike Prinz of Bayer's Board of Management recently articulated the company's predicament, stating, "Bayer is currently in a ...

At the same time, the value of our pipeline is growing by accelerating breakthrough innovations,” said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.